PARTI Overview We are a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. GT-02287 - our lead product candidate, for the treatment of Parkinsons disease, is currently being evaluated in a Phase 1b study in people with Parkinsons disease ...
Q2 FY2026 — expected 2026-08-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001104659-26-035188 | EDGAR | 96K words |
| 2025-03-27 | 2024-12-31 | 0001558370-25-003823 | EDGAR | — |
| 2024-03-26 | 2023-12-31 | 0001558370-24-003943 | EDGAR | — |
| 2023-03-23 | 2022-12-31 | 0001558370-23-004460 | EDGAR | — |
| 2022-03-25 | 2021-12-31 | 0001558370-22-004363 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001104659-25-110347 | EDGAR | 27K words |
| 2025-08-12 | 2025-06-30 | 0001558370-25-011220 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001558370-25-007747 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001558370-24-015709 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011589 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001558370-24-008132 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001558370-23-019014 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001558370-23-014499 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001558370-23-009510 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001558370-22-017414 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001558370-22-012533 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001558370-22-008968 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-26 | 0001104659-26-035174 | EDGAR | 3K words |
| 2026-03-18 | 0001104659-26-029968 | EDGAR | — |
| 2026-02-03 | 0001104659-26-009747 | EDGAR | — |
| 2025-12-18 | 0001104659-25-122353 | EDGAR | — |
| 2025-11-28 | 0001104659-25-116947 | EDGAR | — |
| 2025-11-12 | 0001104659-25-110343 | EDGAR | — |
| 2025-10-14 | 0001104659-25-099343 | EDGAR | — |
| 2025-10-09 | 0001104659-25-098376 | EDGAR | — |
| 2025-10-06 | 0001104659-25-097153 | EDGAR | — |
| 2025-08-12 | 0001558370-25-011218 | EDGAR | — |
99 total filings indexed. 72 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001819411 |
| Ticker | GANX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.gaintherapeutics.com |
| Listed | 2021-03-18 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report